Roche drug that previously failed in Covid-19 pneumonia shows efficacy in Phase III study

Actemra reduced the percentage of patients with Covid-19 pneumonia who progressed to requiring mechanical ventilation, but did not show an improvement in mortality, time to discharge or improvement on an ordinal scale of clinical status. Results of the Phase III COVACTA study, announced in July, were negative.